LS Investment Advisors LLC boosted its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 24.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 8,579 shares of the pharmaceutical company’s stock after buying an additional 1,679 shares during the period. LS Investment Advisors LLC’s holdings in Vertex Pharmaceuticals were worth $1,286,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of VRTX. Dimensional Fund Advisors LP lifted its holdings in Vertex Pharmaceuticals by 3.6% in the second quarter. Dimensional Fund Advisors LP now owns 282,815 shares of the pharmaceutical company’s stock worth $36,445,000 after buying an additional 9,882 shares during the period. AHL Partners LLP purchased a new position in shares of Vertex Pharmaceuticals during the second quarter valued at approximately $916,000. Raymond James Financial Services Advisors Inc. lifted its holdings in shares of Vertex Pharmaceuticals by 27.5% during the second quarter. Raymond James Financial Services Advisors Inc. now owns 6,469 shares of the pharmaceutical company’s stock valued at $834,000 after purchasing an additional 1,397 shares during the last quarter. Sterling Capital Management LLC purchased a new position in shares of Vertex Pharmaceuticals during the second quarter valued at approximately $260,000. Finally, National Asset Management Inc. purchased a new position in shares of Vertex Pharmaceuticals during the second quarter valued at approximately $240,000. Institutional investors and hedge funds own 92.84% of the company’s stock.

Shares of Vertex Pharmaceuticals Incorporated (VRTX) opened at $152.01 on Tuesday. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.79 and a quick ratio of 4.58. Vertex Pharmaceuticals Incorporated has a 1 year low of $84.39 and a 1 year high of $174.96. The company has a market cap of $38,440.00, a P/E ratio of 77.95, a price-to-earnings-growth ratio of 2.23 and a beta of 1.61.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its earnings results on Wednesday, January 31st. The pharmaceutical company reported $0.61 EPS for the quarter, topping analysts’ consensus estimates of $0.53 by $0.08. Vertex Pharmaceuticals had a net margin of 10.59% and a return on equity of 11.02%. The business had revenue of $651.63 million during the quarter, compared to the consensus estimate of $592.49 million. During the same quarter in the previous year, the firm posted $0.35 EPS. The firm’s revenue was up 42.1% on a year-over-year basis. equities analysts expect that Vertex Pharmaceuticals Incorporated will post 1.63 earnings per share for the current year.

Vertex Pharmaceuticals announced that its board has approved a share repurchase program on Wednesday, January 31st that authorizes the company to repurchase $500.00 million in shares. This repurchase authorization authorizes the pharmaceutical company to buy shares of its stock through open market purchases. Shares repurchase programs are generally an indication that the company’s management believes its stock is undervalued.

In other Vertex Pharmaceuticals news, SVP Paul M. Silva sold 2,098 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $163.08, for a total value of $342,141.84. Following the completion of the sale, the senior vice president now owns 17,923 shares of the company’s stock, valued at approximately $2,922,882.84. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, SVP Paul M. Silva sold 9,883 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Friday, February 2nd. The stock was sold at an average price of $173.50, for a total transaction of $1,714,700.50. Following the completion of the sale, the senior vice president now directly owns 25,228 shares of the company’s stock, valued at approximately $4,377,058. The disclosure for this sale can be found here. In the last ninety days, insiders sold 403,165 shares of company stock valued at $62,154,183. 1.80% of the stock is currently owned by insiders.

Several equities analysts have recently issued reports on VRTX shares. Royal Bank of Canada lifted their target price on shares of Vertex Pharmaceuticals from $175.00 to $181.00 and gave the company an “outperform” rating in a report on Wednesday, October 18th. Zacks Investment Research lowered shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, October 24th. Piper Jaffray Companies reiterated an “overweight” rating and set a $205.00 target price on shares of Vertex Pharmaceuticals in a report on Thursday, October 26th. Maxim Group reiterated a “buy” rating and set a $195.00 target price on shares of Vertex Pharmaceuticals in a report on Thursday, October 26th. Finally, HC Wainwright reiterated a “hold” rating and set a $85.00 target price on shares of Vertex Pharmaceuticals in a report on Thursday, October 26th. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and twenty-five have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $180.07.

TRADEMARK VIOLATION NOTICE: This piece of content was published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this piece of content on another site, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://theolympiareport.com/2018/02/13/vertex-pharmaceuticals-incorporated-vrtx-shares-bought-by-ls-investment-advisors-llc.html.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.